PDCD1 and neoplasm: There is a small reduction in tumor size on the last day of study in the 30 mg/kg CCX559 group only; the mechanism is unclear, but an on-target effect can’t be ruled out, given the possibility that the human PD-L1 on A375 cells could activate PD-1 on murine myeloid and NK cells.